UniProtKB/Swiss-Prot P03950: Variant p.Cys63Trp

• Variant information
• Sequence information
• Literature citations
• All

Variant information

Variant position: 63 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: LP/P [Disclaimer: Variants classification is intended for research purposes only, not for clinical and diagnostic use. The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant.] The variants are classified into three categories: LP/P, LB/B and US.

• LP/P: likely pathogenic or pathogenic.
• LB/B: likely benign or benign.
• US: uncertain significance

Residue change: From Cysteine (C) to Tryptophan (W) at position 63 (C63W, p.Cys63Trp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: Change from medium size and polar (C) to large size and aromatic (W) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

• Lowest score: -4 (low probability of substitution).
• Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description: In ALS9; reduced ribonucleolytic activity; low angiogenic activity; reduced mitogenic activity; reduced thermal stability. Any additional useful information about the variant.
Other resources: Links to websites of interest for the variant.

• Variant rs121909539 [ dbSNP | Ensembl ]

Sequence information

Variant position: 63 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 147 The length of the canonical sequence.
Location on the sequence: QGRDDRYCESIMRRRGLTSP C KDINTFIHGNKRSIKAICEN The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

• Type: the type of sequence feature.
• Positions: endpoints of the sequence feature.
• Description: contains additional information about the feature.

Type	Positions	Description
Chain	25 – 147	Angiogenin
Binding site	45 – 45
Binding site	46 – 46
Disulfide bond	50 – 105
Disulfide bond	63 – 116
Mutagenesis	59 – 59	L -> P. Homodimerization is similar to wild-type; causes mislocalization in the cytoplasm; strongly reduces ribonucleolytic activity.
Mutagenesis	64 – 64	K -> Q. Significantly decreases binding affinity for RNH1.
Mutagenesis	68 – 68	T -> A. Decreased ribonuclease activity.
Turn	60 – 63

Literature citations

ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis.
Greenway M.J.; Andersen P.M.; Russ C.; Ennis S.; Cashman S.; Donaghy C.; Patterson V.; Swingler R.; Kieran D.; Prehn J.; Morrison K.E.; Green A.; Acharya K.R.; Brown R.H. Jr.; Hardiman O.;
Nat. Genet. 38:411-413(2006)
Cited for: VARIANTS ALS9 LEU-36; ILE-41; GLU-41; LYS-55; TRP-63; ILE-64 AND VAL-70; Characterization of human angiogenin variants implicated in amyotrophic lateral sclerosis.
Crabtree B.; Thiyagarajan N.; Prior S.H.; Wilson P.; Iyer S.; Ferns T.; Shapiro R.; Brew K.; Subramanian V.; Acharya K.R.;
Biochemistry 46:11810-11818(2007)
Cited for: CHARACTERIZATION OF VARIANTS ALS9 LEU-36; ILE-41; GLU-41; LYS-55; TRP-63; ILE-64 AND VAL-70; CHARACTERIZATION OF VARIANT ALS9 VAL-70; Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis.
van Es M.A.; Schelhaas H.J.; van Vught P.W.; Ticozzi N.; Andersen P.M.; Groen E.J.; Schulte C.; Blauw H.M.; Koppers M.; Diekstra F.P.; Fumoto K.; LeClerc A.L.; Keagle P.; Bloem B.R.; Scheffer H.; van Nuenen B.F.; van Blitterswijk M.; van Rheenen W.; Wills A.M.; Lowe P.P.; Hu G.F.; Yu W.; Kishikawa H.; Wu D.; Folkerth R.D.; Mariani C.; Goldwurm S.; Pezzoli G.; Van Damme P.; Lemmens R.; Dahlberg C.; Birve A.; Fernandez-Santiago R.; Waibel S.; Klein C.; Weber M.; van der Kooi A.J.; de Visser M.; Verbaan D.; van Hilten J.J.; Heutink P.; Hennekam E.A.; Cuppen E.; Berg D.; Brown R.H. Jr.; Silani V.; Gasser T.; Ludolph A.C.; Robberecht W.; Ophoff R.A.; Veldink J.H.; Pasterkamp R.J.; de Bakker P.I.; Landers J.E.; van de Warrenburg B.P.; van den Berg L.H.;
Ann. Neurol. 70:964-973(2011)
Cited for: VARIANTS ALS9 LEU-12; SER-12; ASP-15; GLN-20; SER-20; LEU-36; GLU-41; ASN-52; LYS-55; TRP-63; ILE-64; GLU-64; SER-104; ILE-124; LEU-136; ILE-137; ARG-138 AND HIS-145; VARIANTS ALA-13; ASP-17; ARG-37; VAL-46; ARG-78; GLN-119 AND CYS-145;